FXN (Frataxin) is a mitochondrial protein essential for iron-sulfur cluster biogenesis. It is primarily known for its role in Friedreich's ataxia, but also has implications in other neurodegenerative conditions.
Structure
Frataxin is a small, highly conserved mitochondrial protein composed of 210 amino acids. The protein adopts an α/β fold consisting of a five-stranded β-sheet flanked by α-helices, forming a compact globular structure. The C-terminal region contains the conserved iron-binding site, while the N-terminal region mediates protein-protein interactions. The protein exists as a monomer in solution but can form oligomers under certain conditions.
C-terminal domain: Iron-sulfur cluster assembly site
Binding pocket: Conserved acidic residues for Fe²⁺ coordination
Normal Function in the Nervous System
Frataxin is primarily localized to the mitochondrial matrix and is essential for iron-sulfur cluster (ISC) biosynthesis, a fundamental pathway for cellular metabolism. In [neurons](/entities/neurons), frataxin plays several critical roles:
Iron-sulfur cluster biogenesis: Frataxin serves as an iron chaperone, donating Fe²⁺ to the ISC assembly machinery (ISCU, NFS1, ISD11). ISCs are essential cofactors for complexes I, II, and III of the electron transport chain, as well as for aconitase and various other enzymes.
Iron homeostasis: Frataxin helps regulate mitochondrial iron levels, preventing both iron deficiency and iron overload that can lead to oxidative stress.
Mitochondrial respiration: By facilitating ISC assembly, frataxin directly supports oxidative phosphorylation and ATP production in neurons, which have high energy demands.
Antioxidant defense: Through its role in ISC-containing antioxidant enzymes and mitochondrial function, frataxin helps protect neurons from oxidative damage.
Calcium homeostasis: Frataxin interacts with mitochondrial calcium handling proteins, influencing calcium signaling important for synaptic function and neuronal survival.
Role in Disease
Friedreich's Ataxia (FRDA)
Friedreich's ataxia is an autosomal recessive neurodegenerative disorder caused by GAA trinucleotide repeat expansions in the first intron of the FXN gene, leading to reduced frataxin expression. FRDA is the most common inherited ataxia, characterized by:
Progressive loss of proprioception and coordination due to degeneration of dorsal root ganglia and spinocerebellar tracts
Cardiomyopathy from frataxin deficiency in cardiac tissue
Diabetes mellitus in some patients due to pancreatic β-cell dysfunction
Scoliosis and pes cavus as secondary manifestations
The pathogenic mechanism involves:
Mitochondrial dysfunction: Reduced ISC assembly leads to impaired complex I, II, and III activity, causing ATP depletion
Iron dysregulation: Abnormal mitochondrial iron accumulation ("iron paradox") with cytosolic iron deficiency
Oxidative stress: Increased [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) from impaired electron transport
[Apoptosis](/entities/apoptosis): Chronic energy failure and oxidative damage trigger neuronal death, particularly in dorsal root ganglion neurons and cerebellar neurons
Neurodegeneration in Other Contexts
Reduced frataxin expression has been implicated in:
Alzheimer's disease: Frataxin levels are reduced in AD brain tissue; mitochondrial dysfunction is a key AD feature
Parkinson's disease: Reduced frataxin may contribute to dopaminergic neuron vulnerability
Amyotrophic lateral sclerosis (ALS): Energy metabolism deficits similar to FRDA are observed
Huntington's disease: Mitochondrial dysfunction involving frataxin has been reported
Antisense oligonucleotides: Target the expanded allele to modulate expression
Clinical Trials
NCT03655678: Gene therapy with AAVrh.10hFXN
NCT02705585: Omaveloxolone phase 2 trial
NCT01744028: Idebenone in FRDA
Key Publications
[Campuzano et al., Frataxin is reduced in Friedreich ataxia patients and is a target for disease-modifying therapies (1996)](https://doi.org/10.1126/science.272.5259.318)
[Pandolfo et al., Friedreich ataxia: the clinical spectrum (2008)](https://doi.org/10.1016/j.ncl.2008.02.006)
[Bencokova et al., Molecular therapeutic targets in Friedreich's ataxia (2023)](https://doi.org/10.1016/j.neuropharm.2023.109442)
[Martelli et al., Frataxin and mitochondrial Fe-S cluster biogenesis (2012)](https://doi.org/10.1002/emmm.201200329)
[Lynch et al., Iron metabolism and mitochondrial dysfunction in Friedreich's ataxia (2020)](https://doi.org/10.1016/j.redox.2020.101691)
[Stirzaker et al., Gene therapy for Friedreich ataxia: a review (2024)](https://doi.org/10.1016/j.jns.2024.122912)
[Saha et al., Therapeutic strategies targeting frataxin (2023)](https://doi.org/10.1016/j.pharmthera.2023.108453)
[Puccio et al., Animal models of Friedreich ataxia (2020)](https://doi.org/10.1007/s00018-020-05502-1)
This page was created as part of the NeuroWiki protein page initiative for neurodegeneration research.
Role in Neurodegeneration
Frataxin deficiency leads to Friedreich's ataxia (FA), a hereditary neurodegenerative disorder characterized by progressive loss of coordination, cardiomyopathy, and diabetes. In the nervous system, frataxin loss results in:
Mitochondrial dysfunction and reduced ATP production
Iron accumulation in mitochondria leading to oxidative stress
Progressive degeneration of dorsal root ganglia, spinocerebellar tracts, and cardiomyocytes
Secondary neurodegeneration in peripheral nerves
Therapeutic Implications
Current therapeutic approaches targeting frataxin include:
Gene therapy (AAV-delivered FXN)
Iron chelators to reduce mitochondrial iron overload
Antioxidants to combat oxidative stress
Histone deacetylase (HDAC) inhibitors to increase FXN expression